Dixon Karen O, van der Kooij Sandra W, Vignali Dario A A, van Kooten Cees
Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.
Department of Immunology, University of Pittsburgh, PA, USA.
Eur J Immunol. 2015 Jun;45(6):1736-47. doi: 10.1002/eji.201445217.
IL-35 is a cytokine of the IL-12 family, existing as a heterodimer of IL-12p35 and Ebi3. IL-35 has anti-inflammatory properties and is produced by regulatory T cells in humans and mice, where it is required for optimal suppression of immune responses. Distinct from other IL-12 cytokines, the expression of IL-35 has not been described in antigen-presenting cells. In view of the immune-regulatory properties of IL-35, we investigated the expression, regulation, and function of IL-12p35 and Ebi3 in human monocyte-derived dendritic cells and tolerogenic DCs (tolDCs). These tolDCs do not produce IL-12p70 or the homodimer IL-12p40. We demonstrate that tolDCs completely lack transcriptional expression of IL-12p40. However, tolDCs maintain mRNA expression of IL-12p35 and Ebi3. Using intracellular flow cytometry and Western blot analysis, we show that tolDCs produce Ebi3 and IL-12p35, and both can be enhanced upon stimulation with IFN-γ, LPS, or CD40L. tolDCs supernatants have the capacity to suppress T-cell activation. Using IL12A silencing, we demonstrate that IL-12p35 is required for tolDCs to reach their full suppressive potential. Taken together, our results indicate that tolDCs produce IL-35, providing an additional novel mechanism by which tolDCs elicit their tolerogenic potential.
白细胞介素-35(IL-35)是白细胞介素-12家族的一种细胞因子,以IL-12p35和Ebi3的异二聚体形式存在。IL-35具有抗炎特性,由人和小鼠的调节性T细胞产生,在最佳抑制免疫反应中发挥作用。与其他白细胞介素-12细胞因子不同,抗原呈递细胞中尚未描述IL-35的表达情况。鉴于IL-35的免疫调节特性,我们研究了IL-12p35和Ebi3在人单核细胞衍生的树突状细胞和耐受性树突状细胞(tolDCs)中的表达、调控及功能。这些tolDCs不产生IL-12p70或同二聚体IL-12p40。我们证明tolDCs完全缺乏IL-12p40的转录表达。然而,tolDCs维持IL-12p35和Ebi3的mRNA表达。通过细胞内流式细胞术和蛋白质免疫印迹分析,我们表明tolDCs产生Ebi3和IL-12p35,并且在受到干扰素-γ、脂多糖或CD40L刺激后两者均可增强。tolDCs的上清液具有抑制T细胞活化的能力。通过沉默IL12A,我们证明IL-12p35是tolDCs发挥其完全抑制潜能所必需的。综上所述,我们的结果表明tolDCs产生IL-35,这为tolDCs发挥其耐受性潜能提供了一种新的机制。